Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajinder Parshad

Showing results (121-130 of 122) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 122 results.
Apoptosis : an International Journal on Programmed Cell Death|April 20, 2026
Tumor suppressor candidate 1 (TUSC1) drives oxidative phosphorylation and tumor cell death in colorectal cancerJanvie Manhas, Ruchi Bhardwaj, Sagar Tyagi, et al.
Trials|February 26, 2025
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)Adhip Arora, V Seenu, Rajinder Parshad, et al.
Pageof 13

Showing results (121-130 of 122) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 122 results.
Apoptosis : an International Journal on Programmed Cell Death|April 20, 2026
Tumor suppressor candidate 1 (TUSC1) drives oxidative phosphorylation and tumor cell death in colorectal cancerJanvie Manhas, Ruchi Bhardwaj, Sagar Tyagi, et al.
Trials|February 26, 2025
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)Adhip Arora, V Seenu, Rajinder Parshad, et al.
Pageof 13